DocGo (DCGO) AI Stock Analysis

• Market Cap: $159.43M
• Dividend Yield: N/A
• Average Volume (3M): 504.53K
• Price to Earnings (P/E): 12.7
• Beta (1Y): 1.01
• Revenue Growth: -41.31%
• EPS Growth: -163.08%
• Country: US
• Employees: 3,404
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Care Facilities
• EPS (TTM): -0.11
• Shares Outstanding: 97,808,136
• 10 Day Avg. Volume: 603,612
• 30 Day Avg. Volume: 504,534
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 0.23
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: -8.16
• 1Y Price Target: $3.13
• Price Target Upside: 92.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 54 Neutral
• Price Target: $1.50 ▼(-7.98% Downside)

DocGo's overall stock score reflects significant financial performance challenges, with declining revenue and profitability being the most critical issues. While technical analysis shows some short-term bullish signals, valuation concerns and negative earnings impact the score. The earnings call provided some positive operational insights, but financial stability remains a key risk. The share repurchase program extension is a minor positive factor.

Positive Factors

Business Expansion

The payer business is gaining momentum with new wins, including a new care gap closure program in Southern California and a contract expansion in the Northeast.

Financial Stability

The company has cash and is collecting accounts receivable from the migrant business, which provides a financial runway to ramp up the payer and provider business.

Technological Investment

The core payer and care gap closure business is performing well, with significant investments in Artificial Intelligence and automation.

Negative Factors

EBITDA Decline

There is an alarming rapid deterioration in the business profile, with a significant drop in adjusted EBITDA from the previous year.

Federal Funding Uncertainty

The ability to launch new business and timing of RFP decisions have hit a wall due to uncertainty related to federal funding and program cuts.

Revenue Guidance

Management has chosen to remove the government business completely from its FY25 guide, which resulted in a $115mm decline in guidance at the midpoint.

DocGo Business Overview & Revenue Model

Company Description

DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.

How the Company Makes Money

DocGo makes money through a diversified revenue model that includes service fees for its mobile health services, telehealth consultations, and medical transportation offerings. The company partners with various healthcare providers, insurance companies, and government entities to deliver its services, often entering into contractual agreements that ensure a steady revenue stream. Key revenue streams include billing for patient visits, charges for transportation services, and fees for telehealth consultations. Additionally, partnerships with healthcare systems and insurers help DocGo expand its reach and customer base, contributing significantly to its earnings.

DocGo Financial Statement Overview

Summary

DocGo's financial performance shows a stable balance sheet with manageable debt levels and strong cash flow improvements. However, the company faces profitability challenges with negative net profit margins and declining revenue, indicating operational difficulties.

Income Statement

Gross Profit Margin for TTM is 32.58%, while Net Profit Margin is negative at -0.12%, indicating operational challenges. Revenue has decreased from the previous year, showing a negative growth trend. EBIT and EBITDA margins have declined significantly in the TTM period, pointing to reduced profitability.

Balance Sheet

Debt-to-Equity Ratio for TTM is 0.20, showing moderate leverage. Return on Equity is negative at -0.21%, reflecting losses. Equity Ratio is healthy at 71.82%, indicating strong equity financing. Overall, the company maintains a stable financial structure with manageable debt levels.

Cash Flow

Free Cash Flow has grown significantly in the TTM period. Operating Cash Flow to Net Income Ratio is strong, suggesting robust cash generation relative to reported losses. The company has improved its cash flow position, enhancing financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	435.97M	616.56M	624.29M	440.52M	318.72M	94.09M
Gross Profit	25.42T	213.57M	195.38M	154.72M	109.75M	31.35M
EBITDA	-12.50M	45.80M	32.73M	32.40M	28.07M	-9.25M
Net Income	-18.33M	19.99M	6.86M	34.58M	23.74M	-14.36M
Balance Sheet
Total Assets	10.00T>	455.62M	490.45M	393.28M	309.60M	100.17M
Cash, Cash Equivalents and Short-Term Investments	10.00T>	89.24M	59.29M	157.34M	175.54M	32.42M
Total Debt	60.45T	57.19M	46.50M	19.91M	16.51M	13.89M
Total Liabilities	10.00T>	140.44M	185.28M	114.35M	82.55M	33.23M
Stockholders Equity	10.00T>	320.92M	300.79M	273.23M	219.58M	55.00M
Cash Flow
Free Cash Flow	41.09T	64.50M	-74.35M	23.37M	-8.60M	-16.97M
Operating Cash Flow	43.26T	70.34M	-64.22M	28.87M	-1.95M	-10.65M
Investing Cash Flow	-34.19M	-10.87M	-29.88M	-38.45M	-8.59M	-6.04M
Financing Cash Flow	-31.11M	-24.15M	1.12M	-6.18M	155.21M	-812.09K

DocGo Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.63
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.49, above the 50-day MA of 1.52, and below the 200-day MA of 2.95, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 73.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DCGO.

DocGo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUNA	67 Neutral	$467.76M	11.03	9.93%	―	6.97%	―
Sector *	65 Neutral	¥341.81B	11.08	-0.17%	2.40%	9.51%	-9.51%
TALK	61 Neutral	$423.69M	156.17	2.52%	―	17.43%	―
DCGO	54 Neutral	$159.43M	12.68	-5.98%	―	-41.31%	-163.08%
CYH	50 Neutral	$382.53M	―	39.18%	―	0.80%	-95.01%
INNV	47 Neutral	$476.60M	―	-12.03%	―	12.19%	-1.59%
PIII	44 Neutral	$49.88M	―	-131.17%	―	4.20%	-54.16%

DocGo Corporate Events

DocGo Holds Annual Stockholders Meeting on June 17

On June 17, 2025, DocGo Inc. held its Annual Meeting of Stockholders, where several key decisions were made. The election of three Class I directors was confirmed, and the compensation of named executive officers was approved on a non-binding basis. However, amendments to the company’s charter regarding corporate opportunities and officer exculpation were not approved. Additionally, the appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm for 2025 was ratified.

The most recent analyst rating on (DCGO) stock is a Hold with a $2.85 price target. To see the full list of analyst forecasts on DocGo stock, see the DCGO Stock Forecast page.

DocGo Extends Share Repurchase Program to December

On June 12, 2025, DocGo Inc. announced an extension of its share repurchase program’s expiration date from June 30, 2025, to December 31, 2025, allowing the company to continue purchasing up to $26 million in common stock. This extension provides the company with flexibility to repurchase shares based on market conditions and other factors, potentially impacting its stock value and benefiting shareholders.

The most recent analyst rating on (DCGO) stock is a Hold with a $2.85 price target. To see the full list of analyst forecasts on DocGo stock, see the DCGO Stock Forecast page.